$5.45
0[0.00%]
At close: Apr 25
$5.45
0[0.00%]
After Hours: 4:20PM EDT
Monte Rosa Therapeutics
(NASDAQ:GLUE)Latest News for Monte Rosa Therapeutics Stock (NASDAQ:GLUE)
Monte Rosa Therapeutics Stock (NASDAQ: GLUE)
Categories: All
Tuesday, March 26, 2024
Thursday, March 14, 2024
Friday, February 16, 2024
Thursday, February 15, 2024
- Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: AnalystVandana Singh - Feb 15, 2024, 2:05PM
- Wedbush Initiates Coverage On Monte Rosa Therapeutics with Outperform Rating, Announces Price Target of $11Benzinga Newsdesk - Feb 15, 2024, 8:46AM
Wednesday, January 10, 2024
Monday, January 08, 2024
Thursday, December 14, 2023
Wednesday, December 13, 2023
Thursday, November 09, 2023
- Monte Rosa Therapeutics: Q3 Earnings InsightsBenzinga Insights - Nov 9, 2023, 8:55AM
- Monte Rosa Therapeutics Q3 EPS $(0.70) Beats $(0.72) Estimate; Cash, Cash Equivalents, Restricted Cash, And Marketable Securities Of $183M Sufficient To Fund Planned Operations And Capital Expenditures Into 1H Of 2026Benzinga Newsdesk - Nov 9, 2023, 7:38AM
Thursday, October 19, 2023
Tuesday, October 17, 2023
- Crude Oil Moves Lower; Bank of America Profit Beats ExpectationsLisa Levin - Oct 17, 2023, 2:31PM
- Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Oct 17, 2023, 1:42PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Oct 17, 2023, 1:31PM
- Dow Surges 100 Points; Goldman Sachs Posts Upbeat EarningsLisa Levin - Oct 17, 2023, 11:56AM
- What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?Vandana Singh - Oct 17, 2023, 11:13AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Oct 17, 2023, 9:06AM
- Monte Rosa Therapeutics Announced Interim Data From The Phase 1 Dose Escalation Part Of Its Ongoing Phase 1/2 Study Of MRT-2359 In Patients With MYC-driven Solid TumorsBenzinga Newsdesk - Oct 17, 2023, 7:48AM
- Monte Rosa Therapeutics Announces Collaboration With Roche To Discover Novel Molecular Glue Degraders Targeting Cancer And Neurological Diseases;Monte Rosa To Receive $50M Upfront Payment And Potential Future Payments Of Over $2BBenzinga Newsdesk - Oct 17, 2023, 7:01AM